Table 1. Baseline characteristics of participants who completed the study. The women either received treatment with the vaginal erbium laser (VEL) or vaginal estriol gel supplementation (see text for details). Data are expressed as mean ± standard deviation.
|
VEL group (n = 43) |
Estriol group (n = 19) |
|
|---|---|---|
| Age (years) | 60.9 ± 8.1 | 63 ± 4.5 |
| Age at menopause (years) | 49.3 ± 4.1 | 51.7 ± 3.3 |
| Years since menopause | 12.5 ± 5.8 | 11.8 ± 3.1 |
| Body mass index (kg/m2) | 26.1 ± 3.3 | 25 ± 3.0 |
| FSH (IU/l) | 85.4 ± 7.8 | 81.5 ± 4.5 |
| Estradiol (pg/ml) | 18.4 ± 2.3 | 20.2 ± 3.4 |
FSH, follicle stimulating hormone